

Global Health Unit



Treatments available
at accessible prices



Health system strengthening
focused on public sector and NGOs



Scaling up inclusive businesses
through the Impact fund

“We view Sanofi as *one of the innovators in the industry*. In our view, one of Sanofi's leading differentiators is its creation of a non-profit unit that aims to improve global health”

S&P Global Ratings

Sanofi Impact brand

A platform for new accessible prices



Expanding affordable access for underserved communities



Valyou insulin program in the U.S.

Continued commitment to ensure affordability by lowering out-of-pocket cost of insulin for uninsured patients since 2018

Uninsured people living with diabetes will pay a fixed-cost of \$35 for a 30-day supply of Sanofi insulins

In 2021, program used more than 97,000 times, providing more than \$37 million in savings to people living with diabetes¹

1. Savings based on Valyou program 2021 price of \$99 a month.

sanofi



ESG
appendices



Sanofi ESG Q2 *achievements*

Affordable access



Global Health Unit #Patients treated

Q1 2022	Q2 2022
Malaria 1,024,170 8 countries	Malaria 1,693,770 10 countries
Tuberculosis 35,094 11 countries	Tuberculosis 76,634 13 countries
NCD 46,300 12 countries	NCD 85,956 21 countries


Rare disease vials donation

Q1 2022	Q2 2022
998 patients treated	1,015 patients treated
22,682 vials donated	51,370 vials donated

Global access plan

Q1 2022	Q2 2022
Pilot phase in progress	Pilot completed Blueprint completed

R&D for unmet needs



Polio eradication

Q1 2022	Q2 2022
16 million IPV doses supplied to UNICEF	27 million IPV doses supplied to UNICEF

Sleeping sickness elimination

FY 2020	FY 2021 ²
1.6 million patients tested for HAT	2 million patients tested for HAT
663 patients treated	805 patients treated

Pediatric cancer treatment development

Q1 2022	Q2 2022
1 of the 2 assets identified in protocol preparation for clinical study	1 asset in pre-clinical assessments
	1 asset in protocol preparation for clinical study

Sanofi ESG Q2 *achievements*

Planet care



Blister-free syringe vaccines

Q4 2021

29% of blister free syringe vaccines produced

Q2 2022

Data updated annually

Eco-design

Q1 2022

4 LCAs completed & 1 in progress

Eco-design digital solutions project launched

Q2 2022

5 LCAs completed & 3 in progress

Eco-design digital solutions project in progress

Scope 1 & 2 GHG emissions reduction

Q1 2022

-26% vs 2019

Q2 2022

-27% vs 2019

Renewable electricity & eco-car fleet

Q1 2022

60%¹ renewable electricity

28.7% eco-fleet

Q2 2022

60% renewable electricity

30.4% eco-fleet

In and beyond the workplace



Diverse Senior Leadership

Q1 2022

35.1% of our executives and 40.4% of our senior leaders were women

Q2 2022

35.9% of our executives and 41.1% of our senior leaders were women

Engagement with communities

FY 2021

4,975 volunteers

26,906 hours

Q2 2022

1,998 volunteers

12,687 hours

From Leaders to Citizens

Q1 2022

Rollout planned in 2022

Q2 2022

Sanofi ESG ratings

Rating agencies



SCORE

86/100	22 Medium risk	74/100	A	Climate Change: A Water: A	B	4.2/5	3.47/5	92%	62/100
New rating	▲ 22.9	▼ 86/100	▲ B	▲ A-	= B	= 4.2/5	▲ 2.49/5	▲ 90%	▲ 58/100
One of the highest scores across all sectors globally 80 points for its solid fundamentals & strong preparedness opinion of 6 points	14 th among 455 pharmaceutical companies	9 th in ranking among 91 pharmaceutical companies	4 th among the 6 largest pharmaceutical companies	Leading position	1 st decile of the 476 companies in the industry	With very high rating across the 3 pillars ESG	Top 5 company	Sanofi's disclosure score well above sector disclosure score (74%)	1 st pharmaceutical company out of 57 Score in progress since 2018

▲ Vs previous rating

Scores assigned by the rating agencies are not equivalent.